BB Biotech AG (BBZA.DE) • XETRA
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold BBZA.DE in your mock portfolio yet.
The negative EPS and resulting negative P/E ratio indicate that BB Biotech AG is currently loss-making on an earnings basis. This suggests weak underlying financial performance despite any recent share price strength. Without evidence of a clear path to profitability, earnings fundamentals are a headwind for the stock.
The stock has risen 10.4% over the last month and is trading well above its 200-day moving average, pointing to a strong intermediate uptrend. An RSI of 53.29 is in neutral territory, suggesting the stock is neither overbought nor oversold and that the recent move has not yet become technically stretched.
Alternative data show very limited digital footprint and engagement, with stagnant social media followings and modest web traffic. The absence of job growth suggests no visible expansion push, which may indicate a lack of aggressive growth initiatives or constrained resources.
BB Biotech AG’s stock exhibits strong positive price momentum and a technically favorable setup, but this is counterbalanced by negative earnings and weak alternative data signals. The current picture is of a stock driven more by market sentiment and portfolio/asset expectations than by improving fundamentals or visible growth initiatives.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started